Although data in cultured cells and xenografts, including ours, have indicated that EGFR plays a role in PC progression [68, 69], clinical trials with EGFR inhibitors have shown limited efficacy in PC patients [70, 71]. The gene discussed is EGFR; the disease is pachyonychia congenita.